TLT secures new collaboration with leading UK universities
22 June 2012. Welwyn Garden City, UK. - Tarilian Laser Technologies has announced the development of a new clinical research consortium between TLT and The William Harvey Research Institute (WHRI) at Queen Mary, University of London, which is led by Professor Mark Caulfield, Director of the WHRI.
This consortium aims to further evaluate the utility and performance of
the TLT Sapphire sensor in intensive care medicine, cardiology and primary
care. The Consortium will include key physicians and involves collaboration
with Barts Health NHS Trust, Queen Mary University of London, Imperial
College and Oxford University.
Comments on this development.
Professor Caulfield stated, “ The TLT device is a promising new technology which could offer a significant paradigm shift in clinical care if successful. Our consortium aims to assess performance of TLT Sapphire in various clinical settings, including in ITU and we are looking forward to starting this important programme of work soon.”
Dr Sandeep Shah, CEO of TLT, a graduate of The Royal London Hospital Medical College and alumnus of Queen Mary University of London, as well as Imperial College, London stated: “We are thrilled by this unique consortium and excited that we now have on board some of the key thought leaders in medicine, especially from my old medical school. The consortium will further energise the progress and development of TLT Sapphire and elaborate further on its unique potentials.”
- ends -
About Tarilian Laser TechnologiesTarilian Laser Technologies (TLT) was established in 2006 by Dr Sandeep Shah, CEO, and Nita Shah, Programme Director, to further develop optical technology that they had discovered could measure blood pressure in a unique way. Following completion of the research programme the company filed a series of patents and set up an international R&D team to progress with the development of the sensor technology. TLT has already successfully completed its international FDA and MHRA pivotal regulatory clinical trial, working with global experts in clinical medicine and clinical trials, including from Barts Hospital, London and the William Harvey Institute, London. TLT is now completing the development and entering the manufacturing translation and scale-up programme for its highly innovative consumer blood pressure device that is a stand-alone cuff-less device and has unique features including superior accuracy and ease of use. TLT is expecting first year sales revenue of its TLT Sapphire innovative device to reach over 1 million units. Tarilian Laser Technologies is headquartered in Welwyn Garden City, Hertfordshire, UK.
Dr Sandeep Shah, CEO, Tarilian Laser Technologies. Tel: +44 (0) 1707 356
For further press information, please contact:
Tel : +44 (0)1252 691 590
Medical Technology Business Europe, 29 Pinewood Park, Farnborough, Hampshire, UK